LRI Investments LLC Sells 113 Shares of Amgen Inc. (NASDAQ:AMGN)

LRI Investments LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 4.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,350 shares of the medical research company’s stock after selling 113 shares during the quarter. LRI Investments LLC’s holdings in Amgen were worth $695,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. PYA Waltman Capital LLC raised its holdings in shares of Amgen by 4.3% in the 3rd quarter. PYA Waltman Capital LLC now owns 10,620 shares of the medical research company’s stock valued at $3,422,000 after purchasing an additional 442 shares during the period. Drucker Wealth 3.0 LLC raised its holdings in shares of Amgen by 0.9% in the 3rd quarter. Drucker Wealth 3.0 LLC now owns 10,225 shares of the medical research company’s stock valued at $3,294,000 after purchasing an additional 88 shares during the period. SGL Investment Advisors Inc. bought a new stake in shares of Amgen in the 3rd quarter valued at about $790,000. Nomura Asset Management Co. Ltd. grew its stake in Amgen by 3.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 340,257 shares of the medical research company’s stock valued at $109,634,000 after buying an additional 11,348 shares during the last quarter. Finally, MML Investors Services LLC grew its stake in Amgen by 7.6% in the 3rd quarter. MML Investors Services LLC now owns 192,413 shares of the medical research company’s stock valued at $61,997,000 after buying an additional 13,555 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on AMGN. Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Wolfe Research began coverage on shares of Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 28th. Finally, Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus target price of $323.05.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $277.63 on Tuesday. The company has a market cap of $149.23 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 3.02 and a beta of 0.55. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a 50 day simple moving average of $305.69 and a 200 day simple moving average of $315.66. Amgen Inc. has a one year low of $257.80 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.96 EPS. Research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 9th. Stockholders of record on Monday, November 18th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend was Monday, November 18th. Amgen’s payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.